Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 36

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 36
---
                                                                 |

| • | the number and characteristics of product candidates we in-license or acquire and develop; |

| • | the outcome, timing and cost of regulatory approvals by the EMA, the MHRA, the FDA and any other comparable                              
 foreign regulatory authorities, including the potential for such regulatory authorities to require that we perform more studies, or more 
 costly studies, than those we currently expect;                                                                                          |

| • | the cost of filing, prosecuting, defending and enforcing any patent claims or other intellectual property 
 rights; and                                                                                               |

| • | the effect of competing technological and market developments. |

Further, our forecast also
does not reflect the possibility that we may not be able to access a portion of our existing cash, cash equivalents and investments due
to market conditions. For example, on March 10, 2023, the United States Federal Deposit Insurance Corporation took control and was appointed
receiver of Silicon Valley Bank. If other banks and financial institutions enter receivership or become insolvent in the future in response
to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents
and investments may be threatened and could have a material adverse effect on our business and financial condition.

If a lack of available capital
means that we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition
and results of operations could be materially adversely affected.

| 19 |

In previous years, we and our independent registered public accounting firm have identified material weaknesses in our internal control over financial reporting. Any failure by us to maintain an effective system of internal controls or provide reliable financial and other information in the future, may cause investors to lose confidence in our financial statements and SEC filings and the market price of our securities may be materially and adversely affected.

The Sarbanes-Oxley Act of
2002, or the Sarbanes-Oxley Act, requires, among other things, that we maintain effective internal controls for financial reporting and
disclosure controls and procedures. We are required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on,
among other things, the effectiveness of our internal control over financial reporting. This assessment includes disclosures of any material
weaknesses identified by management in its internal control over financial reporting.

A material weakness is a control
deficiency, or combination of control deficiencies, in internal control over financial reporting that results in more than a reasonable
possibility that a material mis